HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) is set to announce third quarter earning results on Tuesday 10th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, HTGM to report 3Q20 loss of $ 0.08 per share.
For the full year, analysts anticipate top line of $ 9.92 million, while looking forward to loss of $ 0.32 per share bottom line.
Previous Quarter Performance
HTG Molecular Diagnostics, Inc. reported loss for the second quarter of $ 0.09 per share, from the revenue of $ 1.96 million. The quarterly revenues contracted 64.75 percent compared with the same quarter last year. Wall street analysts are predicting, HTGM to report 2Q20 loss of $ 0.08 per share from revenue of $ 1.79 million. The bottom line results missed street analysts by $ 0.01 or 12.5 percent, at the same time, top line results outshined analysts by $ 0.17 million or 9.50 percent.
Stock Performance
Shares of HTG Molecular Diagnostics, Inc. traded up $ 0.01 or 2.16 percent on Monday, reaching $ 0.34 with volume of 1.38 million shares. HTG Molecular Diagnostics, Inc. has traded high as $ 0.34 and has cracked $ 0.33 on the downward trend
According to the previous trading day, closing price of $ 0.34, representing a 22.22 % increase from the 52 week low of $ 0.27 and a 64.13 % decrease over the 52 week high of $ 0.92.
The company has a market capital of $ 23.73 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
HTG Molecular Diagnostics, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.htgmolecular.com
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
